Immunotherapy
Latest News
Cancer groups offer guidance on immune-related adverse events
Both ASCO and NCCN have released guidelines with tips for managing the side effects of cancer immunotherapy agents.
Conference Coverage
ERV expression may predict response to immune checkpoint blockade in ccRCC, other solid tumors
ERV expression may be associated with immune checkpoint pathway activation and response to immune checkpoint therapy in ccRCC.
From the Journals
Two biomarkers predict immunotherapy response for NSCLC
Two biomarkers were associated with poor outcomes for patients with non–small cell lung cancer who were treated with immune checkpoint inhibitors...
Conference Coverage
AML immune profiles correlate with relapse-free survival
SAN FRANCISCO – Immune-enriched AML might be amenable to immunotherapy that is tailored to the bone marrow tumor microenvironment.
From the Journals
CAR T cells produce longest survival in low disease burden ALL patients
The phase 1 trial examines 19-28z CD19 CAR T cells manufactured at Memorial Sloan Kettering Cancer Center.
Conference Coverage
Combination immunotherapy is active in dMMR/MSI-H metastatic colorectal cancer
With median follow-up of 13.4 months, 55% of metastatic CRC patients had a response to the combination of nivolumab and ipilimumab in the...
Feature
Gene therapy moves from promise to reality
Dr. Cynthia Dunbar, of the NIH, talks about the “critical mass of successes” in hematology and what is coming in the future.
From the Journals
Phase 1 study: Human IL-10 plus checkpoint blockade looks promising in RCC, NSCLC
Pegylated human IL-10 + anti–PD-1 therapy is well tolerated and shows promise for the treatment of both RCC and NSCLC.
Conference Coverage
Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomas
ATLANTA – Updated results in 108 patients with refractory B cell lymphomas showed an ORR of 82%, including 58% complete responses, after a median...
Conference Coverage
DNA vaccine + PD-1 blockade shows promise in mCRPC
NATIONAL HARBOR, MD. – Combining PD-1 pathway inhibition with a DNA vaccine led to antitumor changes in mCRPC patients in a randomized clinical...
Conference Coverage
Nivolumab may extend survival in HCC patients
WASHINGTON – About 20% of patients achieved an objective remission that included complete responses in all subgroups of patients.